On October 12, 2022, the American Society of Addiction Medicine (ASAM) released a public policy statement recommending that the federal government extend critical telehealth flexibilities for addiction care that were introduced at the start of the coronavirus disease 2019 (COVID-19) public health emergency (PHE). Specifically, ASAM is recommending that the U.S. Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) grant continued telehealth flexibilities for buprenorphine for opioid use disorder (OUD) in response to the opioid crisis. The use of audio-only technology for buprenorphine treatment for opioid use disorder (OUD) should be . . .
Restricted Content
You must be an Elite member to view this resource.
